Intrathecal Methotrexate for Cerebritis Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow. https://t.co/wTOehtaU27 https://t.co/8Xp0C6tqBe

• https://bit.ly/3nDEMwr

Join RheumNow during the month of April as we discuss Women in Rheumatology, the XX Factor. Sign up to attend our series! https://t.co/e3AJKwnoWs https://t.co/cpUmsOVuAT

• https://bit.ly/3K4apGU

Network metaanalysis of 7 dietary RCTs in high risk CV pts (40 RCTs, 35 548 pts), showed only Mediterranean (OR 0.72) & low fat (OR 0.84) diet reduce all cause mortality; Med-diet also reduced CV mortality (0.55), stroke (0.65) & non-fatal MI (0.48) https://t.co/ibUknLlwOx https://t.co/zRtvXObvg3

• https://bit.ly/40NtS5t

RCT shows vitamin D does not improve psoriasis. 122 mild PSO pts (PASI=3.1) w/ mean low vit D levels 14.9 ng/mL; randomized to vit D (20KIU/wk) or placebo. At 4 mos, vit D levels rose to 30 w/ Rx, but no signif improvement in PASI change, MD global or DLQI https… https://t.co/OI5v1y5t0u

There are 27 US States where Nurse Practitioners have "Full Practice Authority" - including WA, OR, NV, ID, UT, MT, AZ, CO, WY, NM, ND, SD, NE, KS, Minn, NY, ME, VT, NH, MA, CT, RI, MD, DE, DC https://t.co/hA9Sd63bDW https://t.co/9MM6CTH4gX

• https://bit.ly/42VA11y

203 Rheumatology Clinical trials .gov; after 30 mos 17% are unpublished. Published were more likely to be Phase 3 (57% v 29%) or have +primary outcome (65% vs 26%). Unpub authors cite ongoing preparation, sponsor issues, negative results https://t.co/zSxt0W9ZhB https://t.co/k9rCUSel3e

• https://bit.ly/3lYb8S7

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/ZxJylP7IUk https://t.co/Kmx1dkHycM

• https://bit.ly/3zhrpVl

The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu . https://t.co/nzuHh6v0ua

• https://bit.ly/40thmIM

Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat the pain of osteoarthritis. CATS! https://t.co/mqmQ7jzbpj https://t.co/9FrIOAYJwA

• https://bit.ly/3nARvQw

Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/1ZiRX3jUGV https://t.co/k0a54QJ9Hi

• https://bit.ly/3G9lVzF

2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/kX3dg9DGuw https://t.co/b27CX6Bn0h

• https://bit.ly/3G44JeY

LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/VWs0YuF4LD https://t.co/7ydA3bb82j

• https://bit.ly/3FZ7z4H